MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR

Phase 3
Completed
Conditions
Encephalitis, Tick-borne
First Posted Date
2005-09-13
Last Posted Date
2015-05-21
Lead Sponsor
Pfizer
Target Recruit Count
3800
Registration Number
NCT00161824
Locations
🇵🇱

Zespol Opieki Zdrowotnej w Debicy, Debica, Poland

🇵🇱

Wojewodzki Szpital Dzieciecy Oddzial Obserwacyjno - Zakazny A, Kielce, Poland

🇵🇱

"Atopia" Diagnostyka i Leczenie Chorob Alergicznych i Ukladu Oddechowego, Krakow, Poland

and more 4 locations

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.

Phase 2
Completed
Conditions
Tick-borne Encephalitis
First Posted Date
2005-09-13
Last Posted Date
2015-05-21
Lead Sponsor
Pfizer
Registration Number
NCT00161798
Locations
🇩🇪

Mohrenstrasse 8, Coburg, Germany

🇩🇪

Marktplatz 33, Bad Saulgau, Germany

🇩🇪

Berneckstrasse 19, Schrammberg, Germany

and more 20 locations

Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants

Phase 3
Completed
Conditions
Meningitis, Meningococcal
First Posted Date
2005-09-13
Last Posted Date
2015-05-21
Lead Sponsor
Pfizer
Target Recruit Count
330
Registration Number
NCT00161928
Locations
🇩🇪

Marktplatz 3, Bad Saulgau, Germany

🇩🇪

Neuschwansteinstrasse 5, Augsburg, Germany

🇦🇹

Grieskirchner Strasse 17, Wels, Austria

and more 11 locations

Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216

Completed
Conditions
Meningococcal Meninigitis, Serogroup C
First Posted Date
2005-09-13
Last Posted Date
2015-05-21
Lead Sponsor
Pfizer
Target Recruit Count
321
Registration Number
NCT00161941
Locations
🇩🇪

Löpsinger Strasse 8, Nördlingen, Germany

🇩🇪

Solothurner Strasse 2, Heilbronn, Germany

🇩🇪

Berneckstrasse 19, Schrammberg, Germany

and more 8 locations

FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years

Phase 2
Completed
Conditions
Encephalitis, Tick-borne
First Posted Date
2005-09-13
Last Posted Date
2015-05-21
Lead Sponsor
Pfizer
Target Recruit Count
615
Registration Number
NCT00161889
Locations
🇩🇪

Hauptstrasse 9, Bietigheim-Bissingen, Germany

🇩🇪

Marktplatz 33, Bad Saulgau, Germany

🇩🇪

Salzgasse 11, Calw, Germany

and more 16 locations

Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years

Phase 2
Completed
Conditions
Encephalitis, Tick-borne
First Posted Date
2005-09-13
Last Posted Date
2015-05-21
Lead Sponsor
Pfizer
Registration Number
NCT00161746
Locations
🇦🇹

Brauhausgasse 1, Mürzzuschlag, Austria

🇦🇹

Wiener Strasse 50/2, Kapfenberg, Austria

🇦🇹

Fronleichnamsweg 10, Liezen, Austria

and more 4 locations

TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)

Phase 4
Completed
Conditions
Encephalitis, Tick-Borne
First Posted Date
2005-09-13
Last Posted Date
2015-05-21
Lead Sponsor
Pfizer
Target Recruit Count
375
Registration Number
NCT00161967
Locations
🇦🇹

Grieskirchner Strasse 17, Wels, Upper Austria, Austria

🇵🇱

Niepubliczny ZOZ, Zamosc, Poland

🇩🇪

Hauptstrasse 240, Kehl, Germany

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.

Phase 2
Completed
Conditions
Tick-borne Encephalitis
First Posted Date
2005-09-13
Last Posted Date
2015-05-21
Lead Sponsor
Pfizer
Registration Number
NCT00161772
Locations
🇩🇪

Rastatter Strasse 7, Mannheim-Secken, Germany

🇩🇪

Solothurner Strasse 2, Heilbronn, Germany

🇦🇹

Grieskirchner Strasse 17, Wels, Austria

and more 20 locations

Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years

Phase 4
Completed
Conditions
Tick-borne Encephalitis
First Posted Date
2005-09-13
Last Posted Date
2015-05-21
Lead Sponsor
Pfizer
Target Recruit Count
340
Registration Number
NCT00161785
Locations
🇵🇱

Szpital Jana Pawla II Oddzial Neuroinfekcji, Krakow, Poland

🇵🇱

Hospital in Debica - Zespo Opieki Zdrowotnej w Debicy, Debica, Poland

Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years

Phase 3
Completed
Conditions
Tick-borne Encephalitis
First Posted Date
2005-09-13
Last Posted Date
2015-05-21
Lead Sponsor
Pfizer
Registration Number
NCT00161863
Locations
🇵🇱

Szpital Jana Pawla II Odz. Neuroinfekcji, Krakow, Poland

🇩🇪

Solothurner Strasse 2, Heilbronn, Germany

🇵🇱

PANTAMED sp.z.o.o., Olsztyn, Poland

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath